At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 12-20 16:00:00 EST
1.65
+0.05
+3.13%
盘后1.66
+0.01+0.61%
18:26 EST
High1.72Low1.59Vol294.48K
Open1.59D1 Closing1.60Amplitude8.13%
Mkt Cap24.48MTradable Cap19.23MTotal Shares14.84M
T/O489.68KT/O Rate2.53%Tradable Shares11.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Longeveron to Present at Biotech Showcase 2025
GlobeNewswire  ·  12-18
Longeveron to Present at Biotech Showcase 2025
Roth Initiates Longeveron at Buy With $10 Price Target
MT Newswires Live  ·  12-06
Roth Initiates Longeveron at Buy With $10 Price Target
Longeveron initiated with a Buy at Roth MKM
TIPRANKS  ·  12-06
Longeveron initiated with a Buy at Roth MKM
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
GlobeNewswire  ·  12-03
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
GlobeNewswire  ·  12-02
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-25
Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Longeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial Position
TIPRANKS  ·  11-25
Longeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial Position
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
Simply Wall St.  ·  11-15
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
LGVN Highlights Potential Groundbreaking Treatments
Zacks Small Cap Research  ·  11-13
LGVN Highlights Potential Groundbreaking Treatments
Longeveron reports Q3 EPS (34c), consensus (44c)
TIPRANKS  ·  11-13
Longeveron reports Q3 EPS (34c), consensus (44c)
Longeveron Q3 2024 GAAP EPS $(0.34) Beats $(0.44) Estimate, Sales $773.000K Beat $397.000K Estimate
Benzinga  ·  11-13
Longeveron Q3 2024 GAAP EPS $(0.34) Beats $(0.44) Estimate, Sales $773.000K Beat $397.000K Estimate
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire  ·  11-13
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
Longeveron Names Devin Blass Chief Technology Officer
MT Newswires Live  ·  11-11
Longeveron Names Devin Blass Chief Technology Officer
Longeveron appoints Blass as Chief Technology Officer
TIPRANKS  ·  11-11
Longeveron appoints Blass as Chief Technology Officer
Longeveron® Appoints Devin Blass as Chief Technology Officer and Svp of Chemistry, Manufacturing and Controls (Cmc)
THOMSON REUTERS  ·  11-11
Longeveron® Appoints Devin Blass as Chief Technology Officer and Svp of Chemistry, Manufacturing and Controls (Cmc)
Press Release: Longeveron(R) Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
Dow Jones  ·  11-11
Press Release: Longeveron(R) Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
GlobeNewswire  ·  11-05
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-04
Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad24)
THOMSON REUTERS  ·  10-29
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad24)
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
GlobeNewswire  ·  10-29
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--